evipedia.aidev
← Back

Rhodiola rosea for Health & Longevity

Evidence Review created on 08/15/2026 using AI4L / Grok 4.5

Also known as: Golden Root, Arctic Root, Roseroot, Rose Root, Hong Jing Tian, Sedum roseum

Motivation

Rhodiola rosea is a mountain plant whose root has long been used in northern Europe and Asia as a tonic against fatigue. Today the same root extract is taken as a dietary supplement by people who want more reserve under mental or physical load and a calmer response to strain.

Traditional use and modern marketing overlap on a simple idea: the plant helps the body adapt to strain rather than targeting one organ. Laboratory work points to stress-hormone signaling, cellular energy sensors, and antioxidant defenses. Human trials, mostly small and often tied to extract makers, have mainly tested fatigue and endurance. Results are mixed, and many commercial products do not match the extracts used in studies.

This review examines the human and laboratory evidence on Rhodiola rosea for health and longevity. It covers how the extract appears to work, where benefits and risks are documented, what changes those effects, and how practitioners typically source, time, and monitor use.

Benefits - Risks - Protocol - Conclusion

High-level expert and narrative sources that introduce Rhodiola rosea as an adaptogen (a herb taken to help the body handle strain), endurance aid, and laboratory longevity candidate.

Peter Attia’s site returned no Rhodiola rosea pages. Chris Kresser mentions the herb only briefly in a nootropics overview. Lifespan.io has no dedicated article.

Grokipedia

  • Rhodiola rosea

    An encyclopedia-style plant monograph covering botany, traditional use, marker compounds, and the main clinical and laboratory claims.

Examine

  • Rhodiola rosea

    Examine grades human outcomes (cognition, aerobic metrics, fatigue, mood), lists a 288–680 mg SHR-5-equivalent dose band, and flags adulteration and interaction caveats.

ConsumerLab

  • Rhodiola Rosea Supplements Review

    Independent assays of retail extracts for rosavin and salidroside content, plus a public summary of failed labels, dose ranges, and safety cautions.

Systematic Reviews

The five reviews below cover randomized controlled trials (RCTs) of fatigue and sport performance; no systematic review devoted to clinical harms was found.

Mechanism of Action

Rhodiola rosea root contains phenylpropanoids (rosavin, rosin, rosarin) and the phenylethanoid salidroside. These compounds do not act on a single receptor. They shift the hypothalamic-pituitary-adrenal axis (HPA axis, the central stress-hormone circuit) so that cortisol rises less on waking and after strain, as seen in burnout patients given the SHR-5 extract (Olsson 2009). They also support monoamine signaling (serotonin, dopamine, noradrenaline) and, in laboratory assays, weakly inhibit monoamine oxidase (MAO, an enzyme that breaks down those transmitters).

In cells, salidroside activates AMP-activated protein kinase (AMPK, a fuel-sensing switch that turns on when energy is low) and the FOXO/DAF-16 transcription program that the worm C. elegans uses to live longer under mild stress. Separate work shows salidroside binds heat-shock protein 90 (HSP90, a folding chaperone) and lowers its ATPase activity (the ATP-burning enzyme step). Antioxidant enzymes rise and nuclear factor kappa B (NF-κB, an inflammation switch) is damped. These routes are complementary.

Pharmacology is short-acting. After intravenous dosing in rats, salidroside’s plasma half-life is about one hour, with most of a dose recovered in urine (Zhang 2013). Clearance is mainly deglycosylation to p-tyrosol plus glucuronidation and sulfation (sugar- and sulfate-tagging), not a cytochrome P450 (CYP, a liver enzyme family) primary path (Guo 2014). Tissue levels stay below plasma; muscle, fat, ovary, and testis take up more than brain. Human half-life data are sparse, which is why split morning doses appear in many protocols. Commercial extracts vary widely in marker content, so the same milligram dose is not the same preparation.

Historical Context & Evolution

Soviet military and sports physicians in the 1960s–1980s, following Israel Brekhman’s adaptogen program, studied Rhodiola rosea as a fatigue buffer for pilots, soldiers, and night-shift workers. The intended use was not disease treatment; it was to keep performance up under cold, hypoxia, and sleep loss. Scandinavian folk use and Chinese medicine (hong jing tian) treated the same root as a tonic.

Western interest grew after standardized extracts—SHR-5 from the Swedish Herbal Institute (SHI) and later WS 1375 from Dr. Willmar Schwabe—entered European herbal registers. Early placebo-controlled work in physicians on night duty and students sitting exams reported better mental-work scores. Those trials, and a later burnout and depression series, were often designed or funded by the extract makers (Panossian and Wikman were SHI-affiliated; several WS 1375 papers list Schwabe authors). Independent groups later produced mixed results: a University of Alberta nursing-student trial found worse fatigue than placebo (Punja 2014), and a University of Pennsylvania depression trial found no advantage over placebo (Mao 2015).

The shift from “Soviet adaptogen” to longevity candidate came from fly and worm laboratories, especially Mahtab Jafari’s group at UC Irvine, which reported longer Drosophila life that did not collapse when dietary-restriction pathways were broken (Schriner 2013). That laboratory signal, plus endurance and stress trials, is why the herb now sits in health-optimization routines. Commercial quality did not keep pace: phytochemical surveys found widespread substitution with other Rhodiola species. Current scientific opinion is split, not settled.

Expected Benefits

Medium 🟩 🟩

Several industry-linked randomized trials of SHR-5 or WS 1375 report less burnout and better concentration under load, including night-duty physicians and people meeting fatigue-syndrome criteria. A later independent trial in nursing students on shift work found the opposite: vitality fell relative to placebo. Systematic reviewers in 2012 judged the fatigue literature contradictory and at high or unclear risk of bias (Ishaque 2012).

Magnitude: In Olsson 2009, 576 mg/day SHR-5 for 28 days improved Pines burnout and attention versus placebo and flattened the cortisol awakening response. In Punja 2014, 364 mg/day for 42 days worsened RAND-36 vitality (a 0–100 quality-of-life energy subscale) by 17.3 points versus placebo.

Small gains in endurance and lower perceived effort

A 2025 meta-analysis of 26 randomized trials found small improvements in peak oxygen uptake, time to exhaustion, and time-trial speed, with larger drops in creatine kinase (CK, a muscle-damage enzyme) and blood lactate. Acute single doses more consistently help endurance than multi-week courses. Several included trials are small and heterogeneously dosed.

Magnitude: Wang 2025 reported effect sizes of 0.32 for VO2max (peak oxygen uptake), 0.38 for time to exhaustion, and −0.40 for time-trial time. An acute 3 mg/kg dose cut a 6-mile cycling time trial by 0.4 minutes and lowered mean effort ratings (Noreen 2013).

Mild-to-moderate depressive symptoms ⚠️ Conflicted

An SHR-5 trial reported large drops on the Hamilton Depression Rating Scale (a clinician-scored depression inventory) at 340 or 680 mg/day over 6 weeks. A later NIH-funded comparison found Rhodiola rosea no better than placebo and weaker than sertraline, though with fewer adverse events. The World Federation of Societies of Biological Psychiatry and the Canadian Network for Mood and Anxiety Treatments (clinicians who bill conventional mood care) listed rhodiola as not supported for mood disorders (Sarris 2022).

Magnitude: Darbinyan 2007 found significant Hamilton improvement versus placebo at both doses. Mao 2015 Hamilton changes were −5.1 (rhodiola), −4.6 (placebo), and −8.2 (sertraline); group differences were not significant.

Low 🟩

Lower self-reported anxiety under life stress

An open-label generalized-anxiety series and a non-placebo 14-day Vitano study reported less anxiety and stress. No adequately powered placebo-controlled anxiety trial exists.

Magnitude: Bystritsky 2008 Hamilton Anxiety Rating Scale scores (a clinician-scored anxiety inventory) fell from 23.40 to 14.10 over 10 weeks (open-label, n=10). Cropley 2015 found lower anxiety and stress versus untreated controls at 400 mg/day, without a placebo arm.

Faster recovery markers after hard training

Pooled sport trials show lower post-exercise CK, malondialdehyde (a fat-oxidation damage marker), and lactate, and higher antioxidant-enzyme activity. These are blood markers, not proven hypertrophy or injury-rate changes.

Magnitude: Wang 2025 pooled CK effect size −0.84 and lactate −0.87; superoxide dismutase (SOD, an antioxidant enzyme) rose (effect size 1.16). Effects were larger in trained people and in the first 15 minutes after exercise.

Speculative 🟨

Longer life in worms and flies

Extracts extend mean lifespan in C. elegans and Drosophila, including when dietary-restriction genes are disrupted. The basis is invertebrate and mechanistic only; no human longevity trial exists (Wiegant 2009; Jafari 2007; Jiang 2021).

Neuroprotection in laboratory models

Salidroside shows anti-ischemic and anti-senescence effects in rodent and cell models via AMPK and HSP90. Human cognitive-aging outcomes remain untested at a confirmatory scale (Zhang 2023; Zhuang 2019).

Metabolic tone in laboratory models

Salidroside activates AMPK, a fuel-sensing switch linked to metabolic tone, in cells and animals. Human metabolic outcomes remain untested at a confirmatory scale (Zhang 2023).

Benefit-Modifying Factors

  • CYP2C9 genotype: Extensive metabolizers at CYP2C9 (a liver enzyme that clears warfarin and phenytoin) lost more enzyme activity after 14 days of Arctic Root (Thu 2016). No efficacy-related rhodiola gene is established.

  • Baseline stress and fatigue: Trials that enrolled burnout or examination-stress cohorts were more likely to report benefit than trials in already-coping shift workers (Olsson 2009; Punja 2014).

  • Baseline cortisol awakening response: People who entered with a steep morning cortisol rise were those in whom SHR-5 flattened that rise with fatigue scores; an already-flat curve leaves less room on that marker (Olsson 2009).

  • Sex: Fly work shows sex-specific gene and heat-shock responses (Schriner 2013). Human trials enroll both sexes but rarely test a sex-by-treatment interaction; several sport trials are male-only.

  • Pre-existing mood load: Mild-to-moderate depression and burnout were the main psychiatric entry criteria. Severe depression, bipolar illness, and high suicide risk were exclusion criteria in Mao 2015.

  • Age: Open monitoring in adults 50–89 years reported improved physical and cognitive complaints (Fintelmann 2007). Most randomized trials used adults 18–55; dose has not been separately titrated for older users.

Potential Risks & Side Effects

Medium 🟥 🟥

Mild stimulatory and autonomic adverse events

Across randomized and open trials the usual complaints are dizziness, dry mouth, excess saliva, headache, nausea, and insomnia or restlessness when the dose is taken late. Events are generally mild and reverse on stopping. Rates exceed placebo in some but not all studies.

Magnitude: Mao 2015 recorded adverse events in 30.0% on rhodiola versus 16.7% on placebo and 63.2% on sertraline. Kasper 2017 reported 0.015 events per observation day on 400 mg WS 1375.

Authentic-product failure and species substitution

A European market survey found that about one fifth of products labeled Rhodiola rosea lacked rosavin, the species marker, and most of the rest were weaker than registered products or mixed with other Rhodiola species. Users of those products are exposed to unknown chemistry and to failed efficacy, not to a defined toxin.

Magnitude: Booker 2016 found ~20% of commercial products contained no rosavin; of the remainder, about 80% were below registered-product rosavin levels or appeared adulterated. ConsumerLab later flagged U.S. labels that missed claimed marker amounts.

Modest CYP2C9 inhibition

Fourteen days of a commercial Arctic Root product reduced human CYP2C9 metabolic ratio by 21%, with a larger effect in extensive metabolizers. Other tested CYP enzymes did not change in people. Cell assays also show inhibition of CYP3A4 (the main liver enzyme that clears many medicines) and P-glycoprotein (P-gp, a pump that pushes drugs out of cells), not confirmed as large in humans.

Magnitude: Thu 2016 reported a 21% fall in the EXP-3174/losartan ratio (p=0.023). Isolated salidroside looks less interactive in vitro than whole-root extracts (Kasprzyk 2023).

Low 🟥

Possible additive serotonergic effects with antidepressants

Mechanistic papers and isolated reports raise a serotonin-toxicity concern (dangerous excess serotonin with agitation, tremor, or fever) when rhodiola is combined with SSRIs (selective serotonin reuptake inhibitors) or MAO inhibitors. One trial combined rhodiola with sertraline and did not report that syndrome (Gao 2020).

Magnitude: Not quantified in available studies. No controlled trial has measured a serotonin-toxicity incidence; the signal is mechanistic plus isolated reports (Examine safety database; Gao 2020).

Speculative 🟨

Mania in bipolar-spectrum illness

One published case describes hospital-level mania after Rhodiola rosea. No controlled bipolar data exist; the basis is that isolated report (Whig 2022).

Autoimmune flare

Adaptogen lore includes immune stimulation. No quantified human incidence on rhodiola monotherapy exists; the basis is mechanistic and precautionary (ConsumerLab cautions; no dedicated trial).

Low blood glucose

Animal data describe glucose lowering. No quantified human incidence on rhodiola monotherapy exists; the basis is mechanistic and precautionary (ConsumerLab cautions; no dedicated trial).

Risk-Modifying Factors

  • CYP2C9 genotype: Extensive metabolizers lost more CYP2C9 capacity on Arctic Root than intermediate or poor metabolizers, raising interaction risk with narrow-index substrates (Thu 2016).

  • Evening dosing and baseline insomnia: Stimulatory adverse events cluster when the extract is taken late; people with poor sleep onset are the group most often reporting restlessness in open studies (Edwards 2012).

  • Baseline INR, glucose, and blood pressure: A high-target INR (international normalized ratio, the warfarin clotting test) or low fasting glucose leaves less margin for the 21% CYP2C9 shift (Thu 2016).

  • Sex: No consistent human sex difference in adverse-event rates is published. Reproductive tissues take up salidroside in rodents; pregnancy data are absent.

  • Bipolar or unstable mood history: The mania case and the Mao exclusions make prior mania or mixed states a risk amplifier, not a proven dose interaction (Whig 2022).

  • Age and polypharmacy: Older adults more often take warfarin, phenytoin, or multiple CYP2C9 substrates, so the same 21% enzyme shift has more clinical room to matter (Thu 2016).

Key Interactions & Contraindications

  • CYP2C9 substrates (warfarin, phenytoin, celecoxib): Caution. Human data show 21% CYP2C9 inhibition; bleeding or phenytoin toxicity is the stated risk. Drug-level monitoring is the usual mitigation (Thu 2016).

  • CYP3A4 and P-gp substrates (some statins, midazolam, digoxin): Caution, cell-assay evidence only. Hellum 2010 saw strong inhibition that Thu 2016 did not reproduce for CYP3A4 in people.

  • SSRIs and other serotonergic drugs (sertraline, fluoxetine, tramadol, St. John’s wort): Caution. Additive serotonergic tone is the stated risk. Short-term sertraline combination has been used; agitation, tremor, or fever is the watch item (Gao 2020).

  • MAO inhibitors (phenelzine, tranylcypromine): Caution approaching contraindication. Weak MAO inhibition plus a prescription MAO inhibitor is a serotonin- and pressor-risk combination. No safe combination protocol is defined.

  • Stimulant over-the-counter products (pseudoephedrine, high-dose caffeine): Caution. Additive restlessness, pulse rise, and insomnia are the expected effects. Evening combinations with caffeine are the usual problem setting.

  • Other adaptogens and calming combinations (ashwagandha, theanine, magnesium): Additive or opposing. Ashwagandha more often lowers cortisol; rhodiola more often modulates it. Mixed products blur which agent caused insomnia or blood-pressure change.

  • Antihypertensives and hypoglycemic drugs (lisinopril, metformin): Monitor. Occasional blood-pressure and glucose-lowering signals exist without a reliable effect size. Home blood-pressure and fasting-glucose checks cover the risk.

Populations who should avoid Rhodiola rosea:

  • Pregnancy and lactation (no adequate human safety data; Examine and ConsumerLab both list avoidance)
  • Bipolar disorder or prior mania/hypomania (a milder run of elevated mood without full mania)
  • Children and adolescents (almost no trial data)
  • Uncontrolled autoimmune flare (theoretical immune stimulation; evidence absent)
  • People who cannot verify extract authenticity (adulteration risk is the dominant product-level harm)

Risk Mitigation Strategies

  • Authenticated, standardized extract only: Protocols typically use root extract labeled ≥3% rosavins and ≥1% salidroside, preferably third-party tested. This cuts the Booker-type substitution risk.

  • Morning or pre-session timing: The usual pattern is the full daily amount before noon or 30–60 minutes before training. This is the main lever against insomnia.

  • Low start, 3–7 day observation: Common starts are 100–200 mg standardized extract, stepped to 200–400 mg only if sleep and pulse stay quiet. Limits stimulatory adverse events.

  • Warfarin/phenytoin watch: INR (international normalized ratio, the standard warfarin blood-thinning test) or phenytoin level is typically rechecked 3–7 days after a start or stop to catch bleeding or toxicity.

  • No same-week stimulant or SSRI start: Adding rhodiola the same week as a new serotonergic drug or a large caffeine increase is the usual agitation setting.

  • Immediate discontinuation for mood switch: The usual rule is to stop at the first run of decreased need for sleep, racing thought, or new irritability (the published mania pathway).

Therapeutic Protocol

  • Common practitioner range: Standardized root extract 200–400 mg once daily, or 288–576 mg/day of SHR-5-type extract in the fatigue trials. Examine flags a bell-shaped response and treats 680 mg/day as a practical ceiling.

  • Competing schools: SHI-style use is daily low-dose for weeks under load (Panossian, Wikman). Sports practice (Galpin, Huberman) is 100–200 mg before hard sessions. Mao’s psychiatry trial used 340–1,360 mg/day.

  • Time of day: Morning, or 30–60 minutes pre-training. Split only if the total exceeds ~300 mg and the second amount can still land before early afternoon.

  • Half-life: Salidroside’s plasma half-life is about 1 hour after intravenous dosing in rats (Zhang 2013). Human oral half-life is poorly measured.

  • Single versus split: Trials used once daily, twice daily (Vitano or WS 1375 200 mg × 2), or four tablets (Olsson 576 mg). Short half-life favors a split when all-day coverage is the aim.

  • Genetics: CYP2C9 extensive metabolizers are the group in whom interaction—not efficacy—changed in Thu 2016. No common pharmacogenetic panel has a validated rhodiola dose rule.

  • Sex: No validated sex-specific milligram target. Several performance trials enrolled only men; women of childbearing potential were excluded from some psychiatric trials unless using contraception.

  • Age: Adults over 50 appeared in open monitoring at standard capsule doses (Fintelmann 2007). Practitioner protocols typically start at the low end when polypharmacy is present.

  • Baseline state: Higher starting fatigue or burnout was the setting in which SHR-5 separated from placebo. Low-stress, well-slept users have less room to show a benefit.

  • Health conditions: Burnout, occupational night work, and mild depression are the studied states. Unstable bipolar illness, pregnancy, and unverified products sit outside usual protocols.

Discontinuation & Cycling

  • Duration of use: Clinical courses ran 2–12 weeks. Nothing in the human record establishes lifelong daily use; sports users often keep it situational.

  • Withdrawal: No withdrawal syndrome is described. Fatigue or stress scores may return toward baseline after stopping, which is loss of effect, not rebound.

  • Taper: Not required on pharmacokinetic grounds (hours-scale clearance). People on warfarin or phenytoin still need a post-stop INR or level check.

  • Cycling: Huberman and some sports coaches describe 2 weeks on / 2 weeks off or hard-session-only use. Fatigue RCTs instead used continuous daily dosing for 2–8 weeks, with no formal cycle comparison.

Sourcing and Quality

  • Species and markers: True Rhodiola rosea carries rosavins; R. crenulata and other species often do not. A 3% rosavin / 1% salidroside label matching the plant’s natural ratio is the usual quality screen (Booker 2016).

  • Third-party testing: ConsumerLab, USP, NSF, or ISO-accredited assay of rosavins and salidroside is the practical check. DNA barcoding catches species swaps that a salidroside-only assay misses.

  • Registered versus supplement grade: EU traditional-use products (for example WS 1375 / Vitano, Arctic Root SHR-5) are batch-controlled. Unregistered internet powders had the highest adulteration rate in Booker’s survey.

  • Brands that appear in tests or trials: SHR-5 (Swedish Herbal Institute / Arctic Root), WS 1375 (Schwabe / Vitano / Rosalin), and several ConsumerLab-pass retail lines (Thorne, Gaia, and others in the 2016–2026 test sets). Brand lists change with each assay wave.

  • Wild-harvest pressure: Wild R. rosea is over-collected in parts of its range (Brinckmann 2021). Cultivated, documented root is the sustainability screen as well as a quality screen.

Practical Considerations

  • Time to effect: Acute endurance studies measure a change 60 minutes after one dose. Stress and burnout scores often move within 1 week and continue through 4–12 weeks (Kasper 2017).

  • Common pitfalls: Buying a “rhodiola” that is another species; taking it at dinner and blaming the herb for insomnia; adding it the same week as a new SSRI; assuming more than 680 mg will do more (Examine describes a bell-shaped curve).

  • Regulatory status: Sold as a U.S. dietary supplement, not approved as a drug. In the EU it is a traditional herbal product for temporary stress (Anghelescu 2018). The World Anti-Doping Agency does not prohibit it.

  • Cost and access: Typical standardized products cost far less than prescription psychotropics. The scarce resource is a verified extract, not list price. Wild root is the conservation bottleneck.

  • Payer incentives: Insurers and national health systems reimburse generic antidepressants and do not cover rhodiola, so guideline attention and trial funding tilt toward the billed drug rather than the uncovered extract.

Interaction with Foundational Habits

  • Sleep: Direct, potentially blunting. Late doses are the main insomnia trigger (stimulatory monoamine and HPA effects). Morning use in burnout series did not systematically worsen sleep scores (Edwards 2012).

  • Nutrition: Indirect, largely none on diet composition. Oral salidroside absorbs fast; trials used capsules with or without breakfast. No nutrient-depletion signal. Alcohol plus a stimulating extract is an unstudied combination.

  • Exercise: Direct, often potentiating for endurance and perceived effort; mixed for strength-endurance. Acute 200 mg or 3 mg/kg 30–60 minutes pre-session is the studied sport pattern (De Bock 2004; Noreen 2013).

  • Stress management: Direct, modulating rather than flattening cortisol. Olsson’s SHR-5 arm lowered the awakening cortisol rise in fatigue-syndrome patients. It does not replace sleep, load management, or psychotherapy; it is a pharmacologic overlay on those habits.

Monitoring Protocol & Defining Success

Baseline work before a first course is light because Rhodiola rosea is not a metabolic drug with a mandatory safety lab. What is useful is a snapshot of the systems it can nudge: morning cortisol rhythm, fasting glucose, blood pressure, sleep, and mood. People already on warfarin or phenytoin add the matching drug level. The point is to know the individual’s starting line so a later change is not blamed on noise.

Ongoing checks sit at 1 week (sleep, restlessness, blood pressure), 4 weeks (fatigue or training logs, repeat glucose and pressure), and every 3–6 months if use continues. Drug-level rechecks belong 3–7 days after any start or stop in people on CYP2C9 substrates. There is no rhodiola-specific therapeutic blood level.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Morning serum or salivary cortisol Track change from own baseline; functional practice often aims for a clear awakening rise that settles by afternoon The extract can flatten an exaggerated cortisol awakening response Draw 30–45 min after waking; conventional labs quote broad morning ranges (~5–25 µg/dL) that miss rhythm
Fasting plasma glucose 70–85 mg/dL functional target used by many longevity clinics Animal and precautionary notes on glucose lowering Conventional “normal” runs to 99 mg/dL; fast 8–12 h; pair with home readings if on hypoglycemic drugs
Resting blood pressure <120/80 mmHg Occasional pressure-lowering and stimulatory pulse reports Sit 5 min; same cuff and time of day; conventional hypertension threshold is 130/80 mmHg
INR (if on warfarin) Prescriber’s target, often 2.0–3.0 Documents the 21% CYP2C9 shift Recheck 3–7 days after start or stop; not a rhodiola biomarker in untreated people
Body weight / waist Individual baseline Indirect check if appetite or training volume changes Not a rhodiola target; context for sport users
  • Sleep-onset latency and night wakings
  • Afternoon energy and perceived exertion on a familiar session
  • Irritability, pressured speech (talking faster than usual and hard to interrupt), or decreased need for sleep (mood-switch watch)
  • Dry mouth, headache, or restlessness in the first week
  • Training log: same-route time, repeats to fatigue, or session RPE (rating of perceived exertion)

Emerging Research

  • 2025 endurance meta-analysis: Wang et al., 2025 pooled 26 trials and found small performance gains and larger recovery-marker shifts, with better VO2max signals above 600 mg/day. Replication in pre-registered, independently funded cohorts is the open question.

  • New sport trials: Short-term Rhodiola rosea changed anaerobic volume and cognition in trained adults (Koozehchian 2025; NCT07225413) and game-simulation times in basketball players (Wang 2025; NCT07239960).

  • Football decision-making trial: A completed 24-player RCT found 4-week dosing improved Yo-Yo intermittent recovery (a shuttle-run test of stop-and-go endurance), mean sprint time, and decision-making under fatigue versus placebo (NCT07366320; Dou 2026). Replication in larger independent cohorts remains open.

  • Attention-deficit/hyperactivity disorder protocols unpublished: Two Brazil Phase 4 records (NCT02737033, NCT02737020; n=60 each, 800 mg) remain at unknown status years after the listed 2021 completion.

  • Mood evidence may shrink, not grow: The same psychiatry taskforce already listed rhodiola as not supported for mood disorders (Sarris 2022). A larger independent depression RCT matching Mao 2015 would further weaken that use.

  • Invertebrate longevity mechanisms: Salidroside–HSP90 binding and rosavin action on insulin/insulin-like growth factor 1 signaling in C. elegans (Zhang 2023; Liang 2024) refine the worm and fly lifespan story, not a human aging trial.

  • Quality crisis is still live: ConsumerLab’s January 2026 update again flagged U.S. authenticity problems, echoing Booker 2016. Better market assays would raise—or further undercut—confidence in every human outcome above.

Conclusion

Rhodiola rosea is a short-acting root extract used for centuries as a fatigue and stress tonic and now studied as possible support for mental stamina, mood under load, and exercise capacity. The clearest human signal is a modest easing of stress-related tiredness and a small improvement in endurance and perceived effort, mainly with standardized extracts taken in the morning or before work. Those effects sit on a mixed evidence base: several maker-funded trials report benefit, a carefully run nursing-student trial found worse fatigue, and a depression trial did not beat placebo. A recent psychiatry taskforce, whose members bill conventional mood care, did not support use for mood disorders. That disagreement tracks extract type, dose, study quality, and who paid for the work. Insurers and health systems pay for conventional mood drugs and not this extract, which can steer research money and guideline attention toward the billed option.

Risks in trials are usually mild—restlessness, poor sleep if taken late, dry mouth, dizziness. The more serious practical problem is the product itself: a large share of retail extracts fail authenticity tests or contain the wrong species. The extract can slow a liver enzyme that handles warfarin and similar drugs. Animal studies show longer life in worms and flies; no human longevity trial exists.

For a health-optimizing adult, Rhodiola rosea is a low-cost, time-limited experiment with a narrow, reversible side-effect profile and an unusually high quality-control burden—not a proven lifespan intervention.

Top - Benefits - Risks - Protocol